{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:11:27Z","timestamp":1790626287328,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gabapentinoids (i.e., gabapentin and pregabalin) are medications approved for epilepsy, chronic pain, or generalized anxiety disorder. Recently, there have been regular reports of misuse of pregabalin, and to a lesser extent, gabapentin, in particular among opioid and polydrug users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To longitudinally explore the amounts of gabapentinoids dispensed in Lyon's Permanent Access to Healthcare (PASS) units, which offer permanent and free healthcare to precarious populations with no healthcare insurance coverage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected the amounts of pregabalin and gabapentin dispensed in the three PASS units of Lyon and calculated the average doses dispensed monthly between 2016 and the first quarter of 2021 (1Q2021), with and without adjustment for the number of dispensing visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The total doses of gabapentinoid dispensed every month in Lyon's PASS units displayed a 1233% increase for pregabalin, and a 1185% increase for gabapentin, between 2016 and 1Q2021. When adjusted for the number of visits, this increase reached a factor of 8.5 for pregabalin and 8.3 for gabapentin, respectively. However, while the increase in pregabalin dispensing was constant throughout the study period, gabapentin total dispensed doses were more fluctuating over time, and the rise of dispensations was thus less straightforward.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study reveals a local but substantial increase in gabapentinoid use in populations with no social insurance. These findings should be confirmed more widely and plead for the systematic collection of anonymous patient data in free healthcare centers in France.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.12726","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T04:31:14Z","timestamp":1631161874000},"page":"448-452","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gabapentinoid use in French most precarious populations: Insight from Lyon Permanent Access to Healthcare (PASS) units, 2016\u20141Q2021"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-6039","authenticated-orcid":false,"given":"Mathieu","family":"Chappuy","sequence":"first","affiliation":[{"name":"Service Universitaire d'Addictologie de Lyon (SUAL) CH Le Vinatier  Bron France"},{"name":"Service Universitaire d'Addictologie de Lyon (SUAL), GH Centre Hospices Civils de Lyon  Lyon France"},{"name":"CSAPA, GH Nord Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0952-0091","authenticated-orcid":false,"given":"Mikail","family":"Nourredine","sequence":"additional","affiliation":[{"name":"Service hospitalo\u2010universitaire de pharmacotoxicologie de Lyon Hospices Civils de Lyon  Lyon France"},{"name":"Service de recherche et \u00e9pid\u00e9miologie clinique Hospices Civils de Lyon  Lyon France"},{"name":"Laboratoire d'\u00e9valuation et mod\u00e9lisation des effets th\u00e9rapeutiques UMR CNRS 5558  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Clerc","sequence":"additional","affiliation":[{"name":"Service Pharmaceutique CH Le Vinatier  Bron France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Fahmi","sequence":"additional","affiliation":[{"name":"Service Permanence d'Acc\u00e8s aux Soins de Sant\u00e9 CH Le Vinatier  Bron France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Misslin","sequence":"additional","affiliation":[{"name":"Service Pharmaceutique CH Saint Joseph \u2013 Saint Luc  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Berthier","sequence":"additional","affiliation":[{"name":"Service Permanence d'Acc\u00e8s aux Soins de Sant\u00e9, GH Centre Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Laloi","sequence":"additional","affiliation":[{"name":"Service Pharmaceutique, GH Centre Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-3635","authenticated-orcid":false,"given":"Benjamin","family":"Rolland","sequence":"additional","affiliation":[{"name":"Service Universitaire d'Addictologie de Lyon (SUAL) CH Le Vinatier  Bron France"},{"name":"Service Universitaire d'Addictologie de Lyon (SUAL), GH Centre Hospices Civils de Lyon  Lyon France"},{"name":"Service hospitalo\u2010universitaire de pharmacotoxicologie de Lyon Hospices Civils de Lyon  Lyon France"},{"name":"INSERM U1028, CNRS UMR 5292, CRNL Universit\u00e9 de Lyon, UCBL1  Bron France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2016.1202764"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781585623860.as38"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01432-7"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13892"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.639780"},{"key":"e_1_2_12_7_1","unstructured":"Official Journal of the French Republic.[Ordinance of 12 Feb 2021 implementing a part of the regulation of narcotics to pregabalin\u2010based medications and determining the duration of prescription]. (24 Feb 2021).https:\/\/www.legifrance.gouv.fr\/eli\/arrete\/2021\/2\/12\/SSAP2103145A\/jo\/texte(accessed 17 May 2021)."},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536200-000000000-00000"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13115"},{"key":"e_1_2_12_10_1","unstructured":"Agence Nationale du M\u00e9dicament et des produits de sant\u00e9 (ANSM).Pr\u00e9gabaline (Lyrica et g\u00e9n\u00e9riques): modification des conditions de prescription et d\u00e9livrance pour limiter le m\u00e9susage. [Pregabalin (Lyrica and generics): modifications of prescribing and dispensing conditions in view of limiting misuse]. 05\/21\/2021https:\/\/ansm.sante.fr\/actualites\/pregabaline-lyrica-et-generiques-modification-des-conditions-de-prescription-et-delivrance-pour-limiter-le-mesusage(accessed 23 July 2021)."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2014.10.010"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62402-2"},{"key":"e_1_2_12_13_1","unstructured":"Agence Nationale du M\u00e9dicament et des produits de sant\u00e9 (ANSM).Rapport Pr\u00e9gabaline [Pregabalin Report]. 02\/24\/2020.https:\/\/ansm.sante.fr\/uploads\/2021\/03\/01\/20200224-rapport-pregabaline-2020.pdf(accessed 17 May 2021)."},{"key":"e_1_2_12_14_1","first-page":"531","article-title":"\u00c9tat de sant\u00e9 des patients se d\u00e9clarant mineurs non accompagn\u00e9s et non reconnus mineurs : enqu\u00eate r\u00e9trospective au sein de la Permanence d'acc\u00e8s aux soins de sant\u00e9 de l'H\u00f4tel\u2010Dieu [Health condition of patients self\u2010reporting as unaccompanied minors and not recognized as such: Retrospective survey within the H\u00f4tel\u2010Dieu health platform PASS]","volume":"27","author":"Hourdet A","year":"2020","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00985-6"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.12726","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:12:55Z","timestamp":1774336375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/fcp.12726"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12726","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"2021-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}